Visnagin

Research use only, not for human use.

Visnagin has acute hypotensive anti-inflammatory and neuroprotective effects it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Visnagin has acute hypotensive anti-inflammatory and neuroprotective effects it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Visnagin (10 μM; for 4, 8, 16, 24 h) induces CYP1A1 transcription in HepG2 cells. Visnagin (10 μM; for 16 h) elevates CYP1B1 gene expression in an aryl hydrocarbon receptor (AHR)-dependent manner, whereas MNF (3’-methoxy-4’-nitroflavone; 20 μM; pre-treated for 1 h) successfully counteracted this induction. Visnagin also enhances PAI-2 transcription in an AHR-dependent manner.

Visnagin (10, 30, 60 mg/kg; ip; for 7 days) is effective in reducing plasma amylase and lipase levels and reduces Cerulein (50 μg/kg, six, hourly i.p. injections) induced oxidative stress in male Swiss albino mice (age: 6-8 weeks, weighing 20-25 g).Visnagin dose dependently decreases the expression of IL-1β, IL-6, TNF-α and IL-17. It attenuates the levels of nuclear p65-NFκB. Visnagin improves the antioxidant defence by improving Nrf2 expression and halts pancreatic inflammation by suppressing NFκB and nitrotyrosine expression in the acinar cells.

——

Others

Other Targets

Others

——

——

82-57-5

230.22

C13H10O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (217.18 mM)

CC(Oc1cc(occ2)c2c(OC)c11)=CC1=O

——

(-20℃)

With Ice Pack

≥ 2 years